Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 3 2Phase 2 2Phase 1/2 2Phase 2/3 1

Status

Completed 26Terminated 6Withdrawn 3Active not recruiting 3Unknown 2Recruiting 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

repotrectinib 1brigatinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Lymphoma, Large-Cell, Anaplastic × Clear all
NCT04925609 2025-12-05

Briga-PED

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
65 enrolled
LymphoidPlasma cell

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡